David E. Moller

32.1k total citations · 9 hit papers
169 papers, 26.2k citations indexed

About

David E. Moller is a scholar working on Molecular Biology, Physiology and Surgery. According to data from OpenAlex, David E. Moller has authored 169 papers receiving a total of 26.2k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Molecular Biology, 56 papers in Physiology and 42 papers in Surgery. Recurrent topics in David E. Moller's work include Metabolism, Diabetes, and Cancer (66 papers), Peroxisome Proliferator-Activated Receptors (62 papers) and Adipose Tissue and Metabolism (53 papers). David E. Moller is often cited by papers focused on Metabolism, Diabetes, and Cancer (66 papers), Peroxisome Proliferator-Activated Receptors (62 papers) and Adipose Tissue and Metabolism (53 papers). David E. Moller collaborates with scholars based in United States, France and United Kingdom. David E. Moller's co-authors include Joel P. Berger, Jeffrey S. Flier, Gaochao Zhou, Thomas W. Doebber, Laurie J. Goodyear, Margaret Wu, John Ventre, Yuli Chen, Nicolas Musi and Michael F. Hirshman and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

David E. Moller

167 papers receiving 25.4k citations

Hit Papers

Role of AMP-activated protein kinase in mechanism of metf... 1991 2026 2002 2014 2001 2002 2008 2001 2013 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Role of AMP-activated protein kinase in mechanism of metformin action
    2001 4.5k citations Gaochao Zhou, Robert P. Myers et al. Journal of Clinical Investigation profile →
  2. The Mechanisms of Action of PPARs
    2002 2.1k citations Joel P. Berger, David E. Moller profile →
  3. Fibroblast Growth Factor 21 Corrects Obesity in Mice
    2008 890 citations David E. Moller et al. Endocrinology profile →
  4. New drug targets for type 2 diabetes and the metabolic syndrome
    2001 862 citations David E. Moller Nature profile →
  5. The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
    2013 730 citations David E. Moller et al. profile →
  6. Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes
    2002 672 citations Nicolas Musi, Michael F. Hirshman et al. profile →
  7. Insulin Resistance — Mechanisms, Syndromes, and Implications
    1991 640 citations David E. Moller et al. profile →
  8. Potential Role of TNF-α in the Pathogenesis of Insulin Resistance and Type 2 Diabetes
    2000 579 citations David E. Moller Trends in Endocrinology and Metabolism profile →
  9. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.
    1996 558 citations David E. Moller et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David E. Moller United States 72 17.1k 6.9k 5.8k 5.3k 4.5k 169 26.2k
George L. King United States 90 12.6k 0.7× 6.3k 0.9× 7.3k 1.3× 4.0k 0.8× 2.5k 0.6× 276 32.5k
Louis M. Havekes Netherlands 84 7.5k 0.4× 5.3k 0.8× 5.8k 1.0× 7.7k 1.5× 4.0k 0.9× 422 23.1k
Jean‐Charles Fruchart France 94 15.8k 0.9× 5.5k 0.8× 7.3k 1.3× 10.3k 2.0× 5.0k 1.1× 382 31.8k
Neil B. Ruderman United States 97 14.1k 0.8× 13.6k 2.0× 5.1k 0.9× 4.9k 0.9× 6.6k 1.5× 248 29.6k
Fabienne Foufelle France 63 10.8k 0.6× 6.5k 0.9× 3.5k 0.6× 5.7k 1.1× 6.7k 1.5× 135 20.9k
Ira J. Goldberg United States 84 9.1k 0.5× 5.1k 0.7× 7.5k 1.3× 5.9k 1.1× 3.9k 0.9× 336 25.9k
Gregory R. Steinberg Canada 78 12.3k 0.7× 8.8k 1.3× 3.3k 0.6× 4.7k 0.9× 6.2k 1.4× 246 23.5k
Sander Kersten Netherlands 86 11.6k 0.7× 8.5k 1.2× 3.9k 0.7× 2.6k 0.5× 6.1k 1.4× 228 25.3k
Marc Foretz France 70 13.0k 0.8× 5.2k 0.8× 3.7k 0.6× 5.9k 1.1× 3.6k 0.8× 187 20.1k
Kristina Schoonjans Switzerland 89 16.6k 1.0× 8.2k 1.2× 3.8k 0.7× 7.6k 1.4× 6.9k 1.6× 203 32.8k

Countries citing papers authored by David E. Moller

Since Specialization
Citations

This map shows the geographic impact of David E. Moller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Moller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Moller more than expected).

Fields of papers citing papers by David E. Moller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Moller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Moller. The network helps show where David E. Moller may publish in the future.

Co-authorship network of co-authors of David E. Moller

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Moller. A scholar is included among the top collaborators of David E. Moller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Moller. David E. Moller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Harrison, Stephen A., Sébastien Bolze, Sheila H. DeWitt, et al.. (2023). Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1). Journal of Hepatology. 78(5). 914–925. 47 indexed citations
2.
Monternier, Pierre‐Axel, Jaspreet Singh, Parveen Parasar, et al.. (2022). Therapeutic potential of deuterium‐stabilized (R)‐pioglitazone—PXL065—for X‐linked adrenoleukodystrophy. Journal of Inherited Metabolic Disease. 45(4). 832–847. 10 indexed citations
3.
Hallakou‐Bozec, Sophie, Micheline Kergoat, Pascale Fouqueray, Sébastien Bolze, & David E. Moller. (2021). Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action. PLoS ONE. 16(2). e0241651–e0241651. 59 indexed citations
4.
Fouqueray, Pascale, Sébastien Bolze, Julie Dubourg, et al.. (2021). Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study. Cell Reports Medicine. 2(12). 100474–100474. 34 indexed citations
5.
Hallakou‐Bozec, Sophie, Guillaume Vial, Micheline Kergoat, et al.. (2020). Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obesity and Metabolism. 23(3). 664–673. 127 indexed citations
6.
Zhao, Yang, Yan Chen, Tabetha M. Bonacci, et al.. (2008). Identification and Characterization of a Major Liver Lysophosphatidylcholine Acyltransferase. Journal of Biological Chemistry. 283(13). 8258–8265. 159 indexed citations
7.
Chen, Yan, Ming‐Shang Kuo, Shuyu Li, et al.. (2008). AGPAT6 Is a Novel Microsomal Glycerol-3-phosphate Acyltransferase. Journal of Biological Chemistry. 283(15). 10048–10057. 123 indexed citations
8.
Desai, Ranjit C., E. Joseph Metzger, Conrad Santini, et al.. (2005). Design and synthesis of potent and subtype-selective PPARα agonists. Bioorganic & Medicinal Chemistry Letters. 16(6). 1673–1678. 17 indexed citations
9.
Sparrow, Carl P., My‐Hanh Lam, Erik Lund, et al.. (2002). A Potent Synthetic LXR Agonist Is More Effective than Cholesterol Loading at Inducing ABCA1 mRNA and Stimulating Cholesterol Efflux. Journal of Biological Chemistry. 277(12). 10021–10027. 105 indexed citations
10.
Moller, David E. & Douglas A. Greene. (2001). Peroxisome proliferator-activated receptor (PPAR)γ agonists for diabetes. Advances in protein chemistry. 181–212. 31 indexed citations
11.
Zhou, Gaochao, Robert P. Myers, Ying Li, et al.. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. Journal of Clinical Investigation. 108(8). 1167–1174. 406 indexed citations
12.
Campbell, Philip, Deepa Nath, Ann Thomson, et al.. (2001). Diabetes. Nature. 414(6865). 781–781. 1 indexed citations
13.
Thieringer, Rolf, Judy Fenyk‐Melody, Patricia A. Detmers, et al.. (2000). Activation of Peroxisome Proliferator-Activated Receptor γ Does Not Inhibit IL-6 or TNF-α Responses of Macrophages to Lipopolysaccharide In Vitro or In Vivo. The Journal of Immunology. 164(2). 1046–1054. 170 indexed citations
14.
Moller, David E.. (2000). Potential Role of TNF-α in the Pathogenesis of Insulin Resistance and Type 2 Diabetes. Trends in Endocrinology and Metabolism. 11(6). 212–217. 579 indexed citations breakdown →
15.
Zhang, Bei, Karen L. MacNaul, Deborah Szalkowski, et al.. (1999). Inhibition of Adipocyte Differentiation by HIV Protease Inhibitors. The Journal of Clinical Endocrinology & Metabolism. 84(11). 4274–4277. 134 indexed citations
16.
Lim, Hyunjung Jade, R. A. Gupta, Wuhua Ma, et al.. (1999). Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes & Development. 13(12). 1561–1574. 499 indexed citations
17.
Ding, Victor, David E. Moller, William P. Feeney, et al.. (1998). Sex Hormone-Binding Globulin Mediates Prostate Androgen Receptor Action via a Novel Signaling Pathway. Endocrinology. 139(1). 213–218. 58 indexed citations
18.
Kelly, Linda, Pasquale P. Vicario, G M Thompson, et al.. (1998). Peroxisome Proliferator-Activated Receptors γ and α Mediate in Vivo Regulation of Uncoupling Protein (UCP-1, UCP-2, UCP-3) Gene Expression. Endocrinology. 139(12). 4920–4927. 245 indexed citations
19.
Zhao, Yi, et al.. (1995). Divergent Functional Roles for p90 Kinase Domains. Journal of Biological Chemistry. 270(32). 18848–18852. 95 indexed citations
20.
Zhao, Yi, Christian Bjørbæk, Stanislawa Weremowicz, Cynthia C. Morton, & David E. Moller. (1995). RSK3 Encodes a Novel pp90 rsk Isoform with a Unique N-Terminal Sequence: Growth Factor-Stimulated Kinase Function and Nuclear Translocation. Molecular and Cellular Biology. 15(8). 4353–4363. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by George L. King Breakdown of academic impact, for papers by Louis M. Havekes Breakdown of academic impact, for papers by Jean‐Charles Fruchart Breakdown of academic impact, for papers by Neil B. Ruderman Breakdown of academic impact, for papers by Fabienne Foufelle Breakdown of academic impact, for papers by Ira J. Goldberg Breakdown of academic impact, for papers by Gregory R. Steinberg Breakdown of academic impact, for papers by Sander Kersten Breakdown of academic impact, for papers by Marc Foretz Breakdown of academic impact, for papers by Kristina Schoonjans
Rankless by CCL
2026